A5050261888- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Bariatric Surgery and Outcomes
- Obesity and Health Practices
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Obesity, Physical Activity, Diet
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Physical Activity and Health
- Health and Lifestyle Studies
- Eating Disorders and Behaviors
- Healthcare cost, quality, practices
- Lipoproteins and Cardiovascular Health
- Children's Physical and Motor Development
- Sports and Physical Education Research
- Mobile Health and mHealth Applications
- Inflammatory mediators and NSAID effects
- Primary Care and Health Outcomes
- Musculoskeletal Disorders and Rehabilitation
- Health Systems, Economic Evaluations, Quality of Life
- Hydrogen's biological and therapeutic effects
- Gastric Cancer Management and Outcomes
- Body Contouring and Surgery
- Health and Medical Research Impacts
- Mitochondrial Function and Pathology
The University of Texas Health Science Center at Houston
2015-2025
Obesity Medicine Association
2013-2023
The University of Texas at Austin
2016
Texas Medical Association
2016
Duke University
2008
University of South Carolina
2007
Case Western Reserve University
1997
University of Colorado Boulder
1995-1997
Importance The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. Objective To assess the tirzepatide, diet and physical activity, maintenance reduction. Design, Setting, Participants This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries a 36-week, open-label lead-in period followed by 52-week, double-blind, placebo-controlled included adults body mass index greater than or equal to 30 27 weight-related...
Abstract In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse events 17,604 adults with preexisting disease, overweight or obesity, without diabetes. Here this prespecified analysis, we examined effects of on weight and anthropometric outcomes, safety tolerability by baseline body mass index (BMI). patients treated semaglutide, loss continued over 65 weeks was sustained for up to 4 years. At 208 weeks, associated mean (−10.2%), waist circumference...
To determine whether semaglutide slows progression of glycemia in people with cardiovascular disease and overweight or obesity but without diabetes.
How does once-weekly subcutaneous tirzepatide affect maintenance of weight loss in individuals with obesity or overweight?
Objective Obesity Medicine Education Collaborative (OMEC) was formed to develop obesity‐focused competencies and benchmarks that can be used by undergraduate graduate medical education program directors. This article describes the developmental process create competencies. Methods Fifteen professional organizations with an interest in obesity collaborated form OMEC. Using six Core Competencies of Accreditation Council for Graduate Medical as domains a guiding framework, total 36 group...
Abstract Background An international panel of obesity medicine experts from multiple professional organizations examined patterns care and current treatment guidelines to identify areas requiring updating in response emerging science clinical evidence. Aims The focused on medical health societal issues influencing effective identified several unmet needs the definition, assessment, obesity. Methods was held Leesburg, Virginia September 2019. Results panelists recommended addressing these...
Summary The rate of weight reduction during obesity treatment declines over time and eventually reaches a plateau. We investigated factors associated with to plateau (TTWP) in tirzepatide‐treated participants or overweight post‐hoc analysis SURMOUNT‐1 SURMOUNT‐4 trials. Participants adherent tirzepatide achieving ≥5% loss by primary endpoint (week 72 SURMOUNT‐1; week 88 SURMOUNT‐4) were included. Weight was defined as change <5% 12‐week interval all subsequent intervals. TTWP from...
To determine the relationship between exposure and weight-loss trajectories for glucagon-like peptide-1 analogue semaglutide weight management.Data from one 52-week, phase 2, dose-ranging trial (once-daily subcutaneous 0.05-0.4 mg) two 68-week 3 trials (once-weekly 2.4 management in people with overweight or obesity without type 2 diabetes were used to develop a population pharmacokinetic (PK) model describing exposure. An exposure-response change was then developed using baseline...
Objective This study aimed to explore the relationship between an obesity diagnosis and weight loss as a percentage of total body over 9 15 months, using electronic health record data. Methods An observational 688,878 adult patients at systems with BMI ≥ 30 kg/m 2 examined documentation diagnosis. Multivariable logistic regression models were created stepwise backwards elimination procedure identify potential predictors loss. Results Of 30, 44.9% had on claim or problem list; 16.9% 5.9% lost...
<p dir="ltr">Objective: To determine whether semaglutide slows progression of glycemia in people with cardiovascular disease and overweight or obesity but without diabetes. Research Design Methods: In a multicenter, double-blind trial, participants ≥45 years, body mass index ≥27 kg/m2, preexisting diabetes (HbA1c <6.5%) were randomized to receive subcutaneous (2.4 mg weekly) placebo. Major glycemic outcomes HbA1c, proportions achieving biochemical normoglycemia <5.7%) progressing...
Purpose: The purpose of this study was to identify factors associated with physical activity (PA) in women during the first year following high school. Methods: Females from 22 schools (n = 915) completed 3-Day Physical Activity Recall 12th grade and reported if they were sports participants. After graduation, 305 (18.9 ± 0.6 years) International Questionnaire. They time spent per day moderate-to-vigorous PA (MVPA) vigorous (VPA) for previous week. Multiple logistic regression used predict...
Summary Despite the availability of a growing range interventions to assist control body weight for people with excess or obesity, only small proportion achieve their loss goals and are able maintain reductions in long term. Negative attitudes beliefs often found among physicians others involved treating obesity may adversely impact effectiveness management. In this international study, healthcare professionals were invited complete an online survey practice management weight. A total 335...
Despite the advice clinicians have been giving patients about importance of restricting their food intake and increasing physical activity levels, Centers for Disease Control Prevention (CDC) states that 78.6 million adults in United States (US) are still obese. With these statistics mind, this symposium provided insights on genetic, cultural, environmental underpinning obesity discussed latest research pharmacotherapy, surgery, need to individualize treatment.
Obesity is a chronic disease that poses serious health and societal burdens. Although guidelines exist for obesity management in primary care, evaluating the success of treatment programs hampered by lack established, robust quality measures. This study aimed to develop, test feasibility, measures operational tracking, performance, patient-centered care context national collaborative develop model US setting. The authors developed evaluated 7 used track patients with overweight or (n =...
Obesity is a major risk factor for development and worsening of osteoarthritis (OA). Managing obesity with effective weight loss strategies can improve patients' OA symptoms, functionality, quality life. However, little known about the clinical journey patients both obesity. This study aimed to map medical by characterizing roles health care providers, influential factors, how treatment decisions are made.A cross-sectional was completed 304 diagnosed body mass index (BMI) ≥30 kg/m2 101...
<p dir="ltr">Objective: To determine whether semaglutide slows progression of glycemia in people with cardiovascular disease and overweight or obesity but without diabetes. Research Design Methods: In a multicenter, double-blind trial, participants ≥45 years, body mass index ≥27 kg/m2, preexisting diabetes (HbA1c <6.5%) were randomized to receive subcutaneous (2.4 mg weekly) placebo. Major glycemic outcomes HbA1c, proportions achieving biochemical normoglycemia <5.7%) progressing...